As of the latest Form 4 filed Apr 20, 2026.
What Milestone Pharmaceuticals Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 24 most recent filings for MIST.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-04-20 | 2026-04-16 | Oliveto Joseph President and CEO | SSale | −36.5K | $2.26 | $82.5K | Yes (planned) | Form 4 ↗ |
| 2026-01-28 | 2026-01-26 | Nelson Jeffrey Edward Chief Operating Officer | SSale | −12.2K | $1.93 | $23.6K | No | Form 4 ↗ |
| 2026-01-28 | 2026-01-26 | Nelson Jeffrey Edward, Chief Operating Officer | MExercise | +20.1K | — | — | No | Form 4 ↗ |
| 2026-01-28 | 2026-01-26 | Bharucha David Chief Medical Officer | SSale | −12.2K | $1.93 | $23.6K | No | Form 4 ↗ |
| 2026-01-28 | 2026-01-26 | Bharucha David, Chief Medical Officer | MExercise | +20.1K | — | — | No | Form 4 ↗ |
| 2026-01-28 | 2026-01-26 | Hasija Amit CFO & EVP of Corp. Development | SSale | −12.2K | $1.93 | $23.6K | No | Form 4 ↗ |
| 2026-01-28 | 2026-01-26 | Hasija Amit, CFO & EVP of Corp. Development | MExercise | +20.1K | — | — | No | Form 4 ↗ |
| 2026-01-28 | 2026-01-26 | Muller Lorenz Chief Commercial Officer | SSale | −11.2K | $1.93 | $21.6K | No | Form 4 ↗ |
| 2026-01-28 | 2026-01-26 | Muller Lorenz, Chief Commercial Officer | MExercise | +20.1K | — | — | No | Form 4 ↗ |
| 2026-01-28 | 2026-01-26 | Oliveto Joseph President and CEO | SSale | −34.5K | $1.93 | $66.6K | No | Form 4 ↗ |
| 2026-01-28 | 2026-01-26 | Oliveto Joseph, President and CEO | MExercise | +66.6K | — | — | No | Form 4 ↗ |
| 2026-01-28 | 2025-12-15 | Nelson Jeffrey Edward Chief Operating Officer | SSale | −58.0K | $2.32 | $135K | No | Form 4 ↗ |
| 2026-01-28 | 2025-12-15 | Bharucha David Chief Medical Officer | SSale | −58.0K | $2.32 | $135K | No | Form 4 ↗ |
| 2026-01-28 | 2025-12-15 | Hasija Amit CFO & EVP of Corp. Development | SSale | −58.0K | $2.32 | $135K | No | Form 4 ↗ |
| 2026-01-28 | 2025-12-15 | Muller Lorenz Chief Commercial Officer | SSale | −53.6K | $2.32 | $124K | No | Form 4 ↗ |
| 2026-01-28 | 2025-12-15 | Oliveto Joseph President and CEO | SSale | −133K | $2.32 | $309K | No | Form 4 ↗ |
| 2026-01-28 | 2025-12-12 | Nelson Jeffrey Edward Chief Operating Officer | AAward | +100K | — | — | No | Form 4 ↗ |
| 2026-01-28 | 2025-12-12 | Bharucha David Chief Medical Officer | AAward | +100K | — | — | No | Form 4 ↗ |
| 2026-01-28 | 2025-12-12 | Hasija Amit CFO & EVP of Corp. Development | AAward | +100K | — | — | No | Form 4 ↗ |
| 2026-01-28 | 2025-12-12 | Muller Lorenz Chief Commercial Officer | AAward | +100K | — | — | No | Form 4 ↗ |
| 2026-01-28 | 2025-12-12 | Oliveto Joseph President and CEO | AAward | +280K | — | — | No | Form 4 ↗ |
| 2026-01-09 | 2026-01-08 | Oliveto Joseph President and CEO | SSale | −43.0K | $2.25 | $96.8K | Yes (planned) | Form 4 ↗ |
| 2026-01-09 | 2026-01-07 | Oliveto Joseph, President and CEO | SSale | −500.00 | $2.25 | $1.13K | Yes (planned) | Form 4 ↗ |
| 2025-12-11 | 2025-12-09 | Muller Lorenz Chief Commercial Officer | GGift | −25.0K | $0.00 | $0.00 | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also MIST’s full analysis or the market-wide insider trading feed. The tabs above jump to MIST’s other SEC data.
Source: SEC Form 4 filings for MIST, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.